Hyperbaric Oxygen Treatment of Long Covid: Review of the Evidence and Perspective

Abstract

Hyperbaric oxygen therapy (HBOT) has emerged as an effective treatment for Long COVID, a condition affecting tens of millions of people in the US and characterized by persistent and debilitating symptoms following SARS-CoV-2 infection. This analysis explores the mechanisms and clinical evidence supporting the efficacy of HBOT in addressing the complex pathophysiology underlying Long COVID. The authors also discuss the social and economic consequences of this new disease, the barriers to accessing HBO treatment and they propose solutions to these barriers.

Mechanisms of Action:

• Anti-inflammatory effects: HBOT reduces

pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and elevates anti-inflammatory IL-10

• Endothelial protection: Improves endothelial function, enhances nitric oxide bioavailability, and attenuates oxidative stress


• Neuroplasticity: Stimulates stem cell mobilization, mitochondrial biogenesis, and synaptic plasticity


• Angiogenesis: Stimulates development of new small blood vessels in areas of lost microcirculation, relieves tissue and organ hypoxia, and restores function


• Immune Modulation: HBO inhibits abnormal activation of T and B Lymphocytes

Clinical Evidence:

• Randomized controlled trials using computerized cognitive battery testing and standardized SF-36 physical function metrics have demonstrated significant improvements in fatigue, cognitive function, attention, and quality of life.


• Case studies report reduced inflammation, oxidative stress, enhanced lung function and significant improvement in neurocognitive function in Long COVID patients treated with HBO.


• Durable benefits observed up to one-year post-treatment, with greatest improvements in most disturbed


• Controlled studies demonstrate the safety of HBO

The growing list of published scientific studies show that HBOT is effective and safe in treating Long COVID. The effectiveness of HBOT is correlated with its ability to target the likely underlying pathophysiology of Long COVID. Currently, HBOT is the only known single treatment that can improve or reverse the many symptoms across multiple organ systems that define Long COVID. These results have been verified and repeated from multiple clinical trials and case reports across the world. The improvement of these symptoms is also sustained long term.

Long COVID affects at least 25-50 million people in the US and up to 1 billion worldwide. The individual effects are varied and can be mild to severely debilitating. When the disease symptoms are profound, it removes people from the workforce, strains personal relationships, and may require around the clock care. It is estimated that the economic impact may be 100 billion in the US annually and up to two trillion globally.

To date, there is not a widely accepted and effective treatment for all the symptoms of Long COVID. This paper presents a review of current scientific studies that highlight hyperbaric oxygen as an effective treatment, a treatment that can reverse the symptoms of Long COVID in a six to eight-week period and has benefits sustained long term. The authors discuss reasons that this treatment currently sees only limited use and they discuss the current limited availability and cost associated with this treatment. They suggest an alternative form of HBOT implementation that would improve both access and affordability. If these last barriers can be overcome, HBO treatment could become the standard by which people recover from Long COVID.